{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T20:50:06Z","timestamp":1771361406643,"version":"3.50.1"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Menarini Hellas"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.ijcard.2016.06.115","type":"journal-article","created":{"date-parts":[[2016,6,26]],"date-time":"2016-06-26T03:40:01Z","timestamp":1466912401000},"page":"60-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["A literature review to evaluate the clinical and economic value of olmesartan for the treatment of hypertensive patients"],"prefix":"10.1016","volume":"221","author":[{"given":"G.","family":"Kourlaba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Gialama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Tsioufis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Maniadakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2016.06.115_bb0005","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(05)70151-3","article-title":"Global burden of hypertension: analysis of worldwide data","volume":"365","author":"Kearney","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2016.06.115_bb0010","first-page":"37","article-title":"Blood pressure in Canadian adults","volume":"21","author":"Wilkins","year":"2010","journal-title":"Health Rep."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0015","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2016.06.115_bb0020","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0140-6736(07)61299-9","article-title":"Essential hypertension","volume":"370","author":"Messerli","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2016.06.115_bb0025","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jama.290.2.199","article-title":"Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988\u20132000","volume":"290","author":"Hajjar","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2016.06.115_bb0030","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2016.06.115_bb0035","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0140-6736(00)03307-9","article-title":"Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration","volume":"356","author":"Neal","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2016.06.115_bb0040","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.1161\/hc3001.094733","article-title":"Manipulation of the renin\u2013angiotensin system","volume":"104","author":"Givertz","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.06.115_bb0045","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1124\/pr.59.3.3","article-title":"The intrarenal renin\u2013angiotensin system: from physiology to the pathobiology of hypertension and kidney disease","volume":"59","author":"Kobori","year":"2007","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0050","doi-asserted-by":"crossref","first-page":"3A","DOI":"10.1016\/S0002-9149(01)02321-9","article-title":"The role of the renin\u2013angiotensin system in the development of cardiovascular disease","volume":"89","author":"Unger","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0055","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0149-2918(00)83064-7","article-title":"A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or =65years with mild to moderate hypertension","volume":"22","author":"Lacourciere","year":"2000","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0060","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.jhh.1000591","article-title":"A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension","volume":"12","author":"Mimran","year":"1998","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0065","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1097\/00004872-200106001-00006","article-title":"Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist","volume":"19","author":"Puchler","year":"2001","journal-title":"J. Hypertens. Suppl."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0070","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.amjhyper.2004.07.021","article-title":"Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals","volume":"18","author":"Oparil","year":"2005","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0075","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1161\/CIRCULATIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research","volume":"117","author":"Calhoun","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.06.115_bb0080","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0085","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0895-4356(92)90085-2","article-title":"Incorporating variations in the quality of individual randomized trials into meta-analysis","volume":"45","author":"Detsky","year":"1992","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0090","doi-asserted-by":"crossref","first-page":"53","DOI":"10.18553\/jmcp.2003.9.1.53","article-title":"Examining the value and quality of health economic analyses: implications of utilizing the QHES","volume":"9","author":"Ofman","year":"2003","journal-title":"J. Manag. Care Pharm."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0095","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1751-7176.2010.00425.x","article-title":"The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure","volume":"13","author":"Bakris","year":"2011","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"10.1016\/j.ijcard.2016.06.115_bb0100","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1097\/00004872-200106001-00007","article-title":"Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives","volume":"19","author":"Ball","year":"2001","journal-title":"J. Hypertens. Suppl."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0105","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/00044011-200626040-00002","article-title":"Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals","volume":"26","author":"Brunner","year":"2006","journal-title":"Clin Drug Investig."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0110","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00044011-200323070-00001","article-title":"Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension","volume":"23","author":"Brunner","year":"2003","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0115","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.jhh.1001577","article-title":"Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension","author":"Chrysant","year":"2003","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0120","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/01.mbp.0000209087.40117.b3","article-title":"Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate","author":"Chrysant","year":"2006","journal-title":"Blood Press. Monit."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0125","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/BF02850182","article-title":"Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring","author":"Destro","year":"2005","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0130","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3810\/pgm.2012.05.2549","article-title":"Efficacy\/safety of olmesartan medoxomil versus losartan potassium in patients by stage 1 or 2 hypertension","volume":"124","author":"Flack","year":"2012","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0135","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1524-6175.2007.06395.x","article-title":"Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension","volume":"9","author":"Giles","year":"2007","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"10.1016\/j.ijcard.2016.06.115_bb0140","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2165\/00044011-200525070-00006","article-title":"Efficacy and safety of olmesartan in the treatment of mild-to-moderate essential hypertension in chinese patients","author":"Liau","year":"2005","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0145","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1097\/HJH.0b013e32833e116b","article-title":"Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study","volume":"28","author":"Malacco","year":"2010","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0150","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1097\/HJH.0b013e328287ad0d","article-title":"Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension","volume":"25","author":"Mallion","year":"2007","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0155","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/01.hjh.0000378321.09231.a4","article-title":"Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension","author":"Mallion","year":"2010","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0160","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1524-6175.2001.01136.x","article-title":"Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension","volume":"3","author":"Oparil","year":"2001","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"10.1016\/j.ijcard.2016.06.115_bb0165","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s12325-012-0029-5","article-title":"Efficacy\/safety of olmesartan medoxomil versus losartan potassium in naive versus previously treated subjects with hypertension","volume":"29","author":"Punzi","year":"2012","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0170","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00129784-200505010-00006","article-title":"Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan","volume":"5","author":"Smith","year":"2005","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"Suppl. 2","key":"10.1016\/j.ijcard.2016.06.115_bb0175","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/sj.jhh.1001395","article-title":"Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs","volume":"16","author":"Stumpe","year":"2002","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0180","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3810\/pgm.2011.01.2248","article-title":"A randomized, double-blind, forced-titration study to compare olmesartan medoxomil versus losartan potassium in patients with stage 1 and 2 hypertension","volume":"123","author":"Weir","year":"2011","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0185","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/HYPERTENSIONAHA.110.163402","article-title":"Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension","volume":"57","author":"White","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2016.06.115_bb0190","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2165\/00044011-200727080-00003","article-title":"Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study","volume":"27","author":"Barrios","year":"2007","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0195","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2165\/00044011-200929070-00001","article-title":"Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study","volume":"29","author":"Barrios","year":"2009","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0200","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2147\/VHRM.S7003","article-title":"Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study","volume":"5","author":"Barrios","year":"2009","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0205","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/hr.2014.26","article-title":"Efficacy of olmesartan\/amlodipine combination therapy in reducing ambulatory blood pressure in moderate-to-severe hypertensive patients not controlled by amlodipine alone","volume":"37","author":"Bilo","year":"2014","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0210","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2165\/00129784-200909040-00001","article-title":"Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study","author":"Chrysant","year":"2009","journal-title":"Am. J.Cardiovasc. Drugs"},{"key":"10.1016\/j.ijcard.2016.06.115_bb0215","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.clinthera.2008.04.002","article-title":"The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study","author":"Chrysant","year":"2008","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0220","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1751-7176.2009.00159.x","article-title":"Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension","author":"Chrysant","year":"2009","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"10.1016\/j.ijcard.2016.06.115_bb0225","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.amjhyper.2003.11.003","article-title":"Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide","author":"Chrysant","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0230","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1517\/14740338.2013.816674","article-title":"Evaluation of safety and efficacy of a fixed olmesartan\/amlodipine combination therapy compared to single monotherapies","volume":"12","author":"Derosa","year":"2013","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0235","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.archger.2013.04.006","article-title":"Clinical effects of combined olmesartan medoxomil and amlodipine on clinic and ambulatory blood pressure in elderly patients with resistant hypertension","author":"Ding","year":"2013","journal-title":"Arch. Gerontol. Geriatr."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0240","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2165\/11536710-000000000-00000","volume":"30","author":"Fogari","year":"2010","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0245","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/BF02850307","article-title":"Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy","author":"Fogari","year":"2006","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.curtheres.2008.02.003","article-title":"Effectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: a prospective, randomized, open-label, blinded end point (PROBE), parallel-arm study","author":"Fogari","year":"2008","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0255","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1517\/14656566.2012.667077","article-title":"Effects of valsartan versus olmesartan addition to amlodipine\/hydrochlorothiazide combination in treating stage 2 hypertensive patients","volume":"13","author":"Fogari","year":"2012","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0260","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/j.1751-7176.2011.00544.x","article-title":"24-Hour efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: the TRINITY ambulatory blood pressure substudy","volume":"13","author":"Izzo","year":"2011","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"10.1016\/j.ijcard.2016.06.115_bb0265","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1751-7176.2011.00588.x","article-title":"Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension","volume":"14","author":"Kereiakes","year":"2012","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"10.1016\/j.ijcard.2016.06.115_bb0270","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00129784-200707050-00006","article-title":"Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate","volume":"7","author":"Kereiakes","year":"2007","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.ijcard.2016.06.115_bb0275","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.kjms.2012.09.005","article-title":"Efficacy and tolerability between an olmesartan\/amlodipine fixed-dose combination and an amlodipine double dose in mild to moderate hypertension","volume":"29","author":"Lin","year":"2013","journal-title":"Kaohsiung J. Med. Sci."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0280","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00044011-200929060-00005","article-title":"Effective systolic blood pressure reduction with olmesartan medoxomil\/amlodipine combination therapy: post hoc analysis of data from a randomized, double-blind, parallel-group, multicentre study","author":"Mourad","year":"2009","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0285","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/hr.2009.163","article-title":"A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study","volume":"32","author":"Ogihara","year":"2009","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0290","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/FJC.0b013e3181bad74e","article-title":"Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use","volume":"54","author":"Oparil","year":"2009","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0295","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.clinthera.2010.07.008","article-title":"Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study","volume":"32","author":"Oparil","year":"2010","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0300","first-page":"103","article-title":"A comparative study of efficacy & safety of aliskiren as an add on therapy to olmesartan versus olmesartan monotherapy in patients with hypertension","author":"Rajkumar","year":"2014","journal-title":"Indo Global J. Pharm. Sci."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0305","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/jhh.2010.105","article-title":"Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension","volume":"25","author":"Rump","year":"2011","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0310","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1097\/01.hjh.0000186022.74245.01","article-title":"Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension","volume":"23","author":"Sellin","year":"2005","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0315","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.clinthera.2010.04.020","article-title":"Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study","volume":"32","author":"Shimada","year":"2010","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0320","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/0044011-200929010-00002","article-title":"Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study","volume":"29","author":"Volpe","year":"2009","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0325","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/BF03261919","article-title":"Efficacy and safety of triple antihypertensive therapy with the olmesartan\/amlodipine\/hydrochlorothiazide combination","volume":"32","author":"Volpe","year":"2012","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0330","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00044011-200929060-00002","article-title":"Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study","volume":"29","author":"Volpe","year":"2009","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0335","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s12325-014-0117-9","article-title":"Open-label study assessing the long-term efficacy and safety of triple olmesartan\/amlodipine\/hydrochlorothiazide combination therapy for hypertension","author":"Volpe","year":"2014","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0340","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s12272-014-0446-x","article-title":"Efficacy and safety of olmesartan medoxomil\/amlodipine fixed-dose combination for hypertensive patients uncontrolled with monotherapy","volume":"37","author":"Zhu","year":"2014","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0345","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"2013 ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"31","author":"Mancia","year":"2013","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0350","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/sj.jhh.1001451","article-title":"A population-based European cohort study of persistence in newly diagnosed hypertensive patients","volume":"16","author":"Hasford","year":"2002","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0355","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/11319570-000000000-00000","article-title":"Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data","volume":"10","author":"Boersma","year":"2010","journal-title":"Am. J. Cardiovasc. Drugs."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0360","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00019053-200321010-00005","article-title":"Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan","volume":"21","author":"Simons","year":"2003","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.ijcard.2016.06.115_bb0365","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1291\/hypres.31.1373","article-title":"Cost-utility analysis of antihypertensive combination therapy in Japan by a Monte Carlo simulation model","volume":"31","author":"Saito","year":"2008","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0370","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1185\/03007991003711045","article-title":"Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension","volume":"26","author":"Miller","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0375","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3111\/13696998.2011.595463","article-title":"Choice of angiotensin receptor blocker in moderate hypertension. A UK-based cost-benefit comparison of olmesartan- and candesartan-based regimens","volume":"14","author":"Belsey","year":"2011","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0380","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF03261842","article-title":"Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis","volume":"12","author":"Wang","year":"2012","journal-title":"Am. J. Cardiovasc. Drugs."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0385","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1524-6175.2004.02632.x","article-title":"Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies","volume":"6","author":"Ram","year":"2004","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"10.1016\/j.ijcard.2016.06.115_bb0390","first-page":"91","article-title":"Critical appraisal of amlodipine and olmesartan medoxomil fixed-dose combination in achieving blood pressure goals","volume":"3","author":"Basile","year":"2010"},{"key":"10.1016\/j.ijcard.2016.06.115_bb0395","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2165\/11206770-000000000-00000","article-title":"Olmesartan medoxomil\/amlodipine\/hydrochlorothiazide: fixed-dose combination in hypertension","author":"Deeks","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.ijcard.2016.06.115_bb0400","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2147\/vhrm.2006.2.4.401","article-title":"Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension","volume":"2","author":"Greathouse","year":"2006","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0405","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2147\/VHRM.S16852","article-title":"Olmesartan\/amlodipine: a review of its use in the management of hypertension","volume":"7","author":"Kreutz","year":"2011","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0410","first-page":"73","article-title":"Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination","volume":"4","author":"Punzi","year":"2011"},{"key":"10.1016\/j.ijcard.2016.06.115_bb0415","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2147\/VHRM.S3642","article-title":"Clinical efficacy and safety of olmesartan\/hydrochlorothiazide combination therapy in patients with essential hypertension","volume":"4","author":"Ruilope","year":"2008","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.ijcard.2016.06.115_bb0420","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2165\/00003495-200969060-00005","article-title":"Olmesartan medoxomil\/amlodipine","volume":"69","author":"Sanford","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.ijcard.2016.06.115_bb0425","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.2165\/00003495-200868090-00005","article-title":"Olmesartan medoxomil: a review of its use in the management of hypertension","volume":"68","author":"Scott","year":"2008","journal-title":"Drugs"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316311196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316311196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T05:26:01Z","timestamp":1656739561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527316311196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":85,"alternative-id":["S0167527316311196"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.06.115","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A literature review to evaluate the clinical and economic value of olmesartan for the treatment of hypertensive patients","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.06.115","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}